Autopsy report · NCT00209079

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

“Terminated 4/17/07. Drug sponsor withdrew.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year after it had already started.
• Ran for about 2 years 7 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Emory University

Sponsor type

University, hospital or other

Conditions

Gastric Adenocarcinoma

Interventions

Gleevec, Taxotere

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
  “Terminated due to the sponsor's decision.” (75% match in meaning)
• A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
  “Pharmaceutical sponsor withdrew financial support.” (75% match in meaning)
• Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
  “Terminated by sponsor” (74% match in meaning)
• Lapatinib and Bortezomib in Patients With Advanced Malignancies
  “Drug support withdrawn” (74% match in meaning)
• Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers
  “Sponsor Terminated” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.